Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Eddie Hickman maintains a Buy rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $40 to $42.
June 16, 2023 | 3:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Eddie Hickman maintains a Buy rating on Tarsus Pharmaceuticals and raises the price target from $40 to $42.
The news of Guggenheim maintaining a Buy rating and raising the price target for Tarsus Pharmaceuticals is positive for the company's stock. This indicates that the analyst has confidence in the company's growth potential and future performance. As a result, this news is likely to have a positive short-term impact on TARS stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100